View Exam | PowerPak

1. Which of the following statements regarding depression, anxiety, and psychosis in patients with Parkinson's disease (PD) is TRUE?

A. The prevalence of depression and anxiety in patients with PD is the same as in the general population. B. Non-visual hallucinations are more common than visual hallucinations in patients with PD. C. Anxiety in patients with PD can worsen motor symptoms such as tremor and dyskinesia. D. Depression is not a risk factor for psychosis in patients with PD.

2. MR is a 67-year-old female with Parkinson's disease (PD). She has been experiencing hallucinations after her doctor increased the dose of her carbidopa/levodopa to better address her PD symptoms. Which of the following would be the MOST APPROPRIATE next step in therapy to manage MR's hallucinations while maintaining appropriate management of her PD?

A. Reduce her carbidopa/levodopa dose and add olanzapine to her current treatment regimen B. Add risperidone to her current treatment regimen C. Add pimavanserin to her current treatment regimen D. Add aripiprazole to her current treatment regimen

3. Which of the following statements regarding the use of selective serotonin reuptake inhibitors (SSRIs) in patients with Parkinson's disease (PD) who are experiencing depression is TRUE?

A. SSRIs can be associated with hypernatremia. B. The minimum effective dose of citalopram in the elderly is 20 mg/day. C. Fluoxetine is the only SSRI that is approved by the US Food and Drug Administration for treating depression in patients with PD. D. Paroxetine should be avoided in elderly patients with PD due to anticholinergic burden.

4. Which of the following medications is approved by the US Food and Drug Administration for the treatment of dementia in patients with Parkinson's disease?

A. Rivastigmine B. Galantamine C. Donepezil D. Memantine

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding depression, anxiety, and psychosis in patients with Parkinson's disease (PD) is TRUE?

3. Which of the following statements regarding the use of selective serotonin reuptake inhibitors (SSRIs) in patients with Parkinson's disease (PD) who are experiencing depression is TRUE?

4. Which of the following medications is approved by the US Food and Drug Administration for the treatment of dementia in patients with Parkinson's disease?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding depression, anxiety, and psychosis in patients with Parkinson's disease (PD) is TRUE?

3. Which of the following statements regarding the use of selective serotonin reuptake inhibitors (SSRIs) in patients with Parkinson's disease (PD) who are experiencing depression is TRUE?

4. Which of the following medications is approved by the US Food and Drug Administration for the treatment of dementia in patients with Parkinson's disease?

« Return to Activity

Customers who Purchased
this Activity also Purchased